Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy
Soluble human interleukin‐6 receptor (sIL‐6R) was measured in the serum of 30 healthy individuals, 32 individuals with monoclonal gammopathy of undetermined significance (MGUS), 20 patients with early multiple myeloma (MM) and 54 patients with overt MM. The serum activity recognized by an immunoradi...
Gespeichert in:
| Veröffentlicht in: | European journal of immunology 1993-04, Vol.23 (4), p.820-824 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 824 |
|---|---|
| container_issue | 4 |
| container_start_page | 820 |
| container_title | European journal of immunology |
| container_volume | 23 |
| creator | Gaillard, Jean‐Philippe Bataille, Régis Brailly, Hervé Zuber, Caroline Yasukawa, Kiyoshi Attal, Michel Maruo, Naoko Taga, Tetsuya Kishimoto, Tadamitsu Klein, Bernard |
| description | Soluble human interleukin‐6 receptor (sIL‐6R) was measured in the serum of 30 healthy individuals, 32 individuals with monoclonal gammopathy of undetermined significance (MGUS), 20 patients with early multiple myeloma (MM) and 54 patients with overt MM. The serum activity recognized by an immunoradiometric assay was determined to be sIL‐6R, because of its binding capacity to IL‐6 and its molecular mass of 55 kDa.
All sera of healthy individuals contained sIL‐6R (mean value: 89 ng/ml, range 17‐300 ng/ml). Serum sIL‐6R levels were increased by 51% in patients with MGUS (mean value: 135 ng/ml, p |
| doi_str_mv | 10.1002/eji.1830230408 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75654355</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1443378274</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4628-6dacd364e924dfbd605ec05ab5630384132aa238dfd74c92e42a8ca5268cc84c3</originalsourceid><addsrcrecordid>eNqFkT1vFDEQhi0ECkegpUNygRDNHv5eb4miABdFooF6NeedzTl47cPeTXRdfgK_kV_CHndKqEg1xfPMOyO9hLzmbMkZEx_w2i-5lUxIpph9QhZcC14prvhTsmCMq0o0lj0nL0q5Zow1Rjcn5MQqbWUtF-RuFV1GKNhRiB3d-KtN2NEywjogDXiDodDU036KbvQpQqAlhWkPfRwxB5x--Pj77pehGR1ux5RnQAtm2K9tYfQYx0Jv_bihQ4rJhb8hVzAMaaab3UvyrIdQ8NVxnpLvn86_nX2pLr9-Xp19vKycMsJWpgPXSaOwEarr151hGh3TsNZGMmkVlwJASNv1Xa1cI1AJsA60MNY5q5w8Je8Ouducfk5YxnbwxWEIEDFNpa210Upq_ajIja454_Usvv-_qJSUtRW1mtXlQXU5lZKxb7fZD5B3LWftvsZ2rrF9qHFeeHPMntYDdvf6sbeZvz1yKA5CnyE6X-41VavGNvuY5qDd-oC7R4625xerf174A957uIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1443378274</pqid></control><display><type>article</type><title>Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Gaillard, Jean‐Philippe ; Bataille, Régis ; Brailly, Hervé ; Zuber, Caroline ; Yasukawa, Kiyoshi ; Attal, Michel ; Maruo, Naoko ; Taga, Tetsuya ; Kishimoto, Tadamitsu ; Klein, Bernard</creator><creatorcontrib>Gaillard, Jean‐Philippe ; Bataille, Régis ; Brailly, Hervé ; Zuber, Caroline ; Yasukawa, Kiyoshi ; Attal, Michel ; Maruo, Naoko ; Taga, Tetsuya ; Kishimoto, Tadamitsu ; Klein, Bernard</creatorcontrib><description>Soluble human interleukin‐6 receptor (sIL‐6R) was measured in the serum of 30 healthy individuals, 32 individuals with monoclonal gammopathy of undetermined significance (MGUS), 20 patients with early multiple myeloma (MM) and 54 patients with overt MM. The serum activity recognized by an immunoradiometric assay was determined to be sIL‐6R, because of its binding capacity to IL‐6 and its molecular mass of 55 kDa.
All sera of healthy individuals contained sIL‐6R (mean value: 89 ng/ml, range 17‐300 ng/ml). Serum sIL‐6R levels were increased by 51% in patients with MGUS (mean value: 135 ng/ml, p<0.005), by 44% in patients with early myeloma (mean value: 128 ng/ml, p<0.001) and by 116 % in patients with overt MM (mean value: 193 ng/ml, p<0.001). In patients with MM, a complete lack of correlation (p>0.7) was found between serum sIL‐6R levels and other previously recognized prognostic factors in this disease, particularly serum IL‐6 levels and those factors related to tumor cell mass. The independence of serum sIL‐6R levels on tumor cell mass was directly demonstrated by studying four patients with MM treated with autologous bone marrow transplantation for periods of between 320 and 760 days. These levels were found to be remarkably stable and constant, independent of whether patients relapsed or achieved complete remission. Finally, physiological concentrations of sIL‐6R were found to increase by tenfold the sensitivity of human myeloma cell lines to IL‐6. These observations suggest a high control of the sIL‐6R level in vivo, and, possibly, an important functional role of this circulating protein in patients with monoclonal gammopathies.</description><identifier>ISSN: 0014-2980</identifier><identifier>EISSN: 1521-4141</identifier><identifier>DOI: 10.1002/eji.1830230408</identifier><identifier>PMID: 8458373</identifier><identifier>CODEN: EJIMAF</identifier><language>eng</language><publisher>Weinheim: WILEY‐VCH Verlag GmbH</publisher><subject>Biological and medical sciences ; Female ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Interleukin-6 - metabolism ; Interleukin‐6 ; Male ; Medical sciences ; Monoclonal gammopathy ; Monoclonal Gammopathy of Undetermined Significance - blood ; Multiple Myeloma - blood ; Receptors, Immunologic - chemistry ; Receptors, Immunologic - metabolism ; Receptors, Interleukin-6 ; Solubility ; Soluble interleukin‐6 receptor ; Time Factors</subject><ispartof>European journal of immunology, 1993-04, Vol.23 (4), p.820-824</ispartof><rights>Copyright © 1993 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4628-6dacd364e924dfbd605ec05ab5630384132aa238dfd74c92e42a8ca5268cc84c3</citedby><cites>FETCH-LOGICAL-c4628-6dacd364e924dfbd605ec05ab5630384132aa238dfd74c92e42a8ca5268cc84c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Feji.1830230408$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Feji.1830230408$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4749898$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8458373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gaillard, Jean‐Philippe</creatorcontrib><creatorcontrib>Bataille, Régis</creatorcontrib><creatorcontrib>Brailly, Hervé</creatorcontrib><creatorcontrib>Zuber, Caroline</creatorcontrib><creatorcontrib>Yasukawa, Kiyoshi</creatorcontrib><creatorcontrib>Attal, Michel</creatorcontrib><creatorcontrib>Maruo, Naoko</creatorcontrib><creatorcontrib>Taga, Tetsuya</creatorcontrib><creatorcontrib>Kishimoto, Tadamitsu</creatorcontrib><creatorcontrib>Klein, Bernard</creatorcontrib><title>Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy</title><title>European journal of immunology</title><addtitle>Eur J Immunol</addtitle><description>Soluble human interleukin‐6 receptor (sIL‐6R) was measured in the serum of 30 healthy individuals, 32 individuals with monoclonal gammopathy of undetermined significance (MGUS), 20 patients with early multiple myeloma (MM) and 54 patients with overt MM. The serum activity recognized by an immunoradiometric assay was determined to be sIL‐6R, because of its binding capacity to IL‐6 and its molecular mass of 55 kDa.
All sera of healthy individuals contained sIL‐6R (mean value: 89 ng/ml, range 17‐300 ng/ml). Serum sIL‐6R levels were increased by 51% in patients with MGUS (mean value: 135 ng/ml, p<0.005), by 44% in patients with early myeloma (mean value: 128 ng/ml, p<0.001) and by 116 % in patients with overt MM (mean value: 193 ng/ml, p<0.001). In patients with MM, a complete lack of correlation (p>0.7) was found between serum sIL‐6R levels and other previously recognized prognostic factors in this disease, particularly serum IL‐6 levels and those factors related to tumor cell mass. The independence of serum sIL‐6R levels on tumor cell mass was directly demonstrated by studying four patients with MM treated with autologous bone marrow transplantation for periods of between 320 and 760 days. These levels were found to be remarkably stable and constant, independent of whether patients relapsed or achieved complete remission. Finally, physiological concentrations of sIL‐6R were found to increase by tenfold the sensitivity of human myeloma cell lines to IL‐6. These observations suggest a high control of the sIL‐6R level in vivo, and, possibly, an important functional role of this circulating protein in patients with monoclonal gammopathies.</description><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Interleukin-6 - metabolism</subject><subject>Interleukin‐6</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Monoclonal gammopathy</subject><subject>Monoclonal Gammopathy of Undetermined Significance - blood</subject><subject>Multiple Myeloma - blood</subject><subject>Receptors, Immunologic - chemistry</subject><subject>Receptors, Immunologic - metabolism</subject><subject>Receptors, Interleukin-6</subject><subject>Solubility</subject><subject>Soluble interleukin‐6 receptor</subject><subject>Time Factors</subject><issn>0014-2980</issn><issn>1521-4141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkT1vFDEQhi0ECkegpUNygRDNHv5eb4miABdFooF6NeedzTl47cPeTXRdfgK_kV_CHndKqEg1xfPMOyO9hLzmbMkZEx_w2i-5lUxIpph9QhZcC14prvhTsmCMq0o0lj0nL0q5Zow1Rjcn5MQqbWUtF-RuFV1GKNhRiB3d-KtN2NEywjogDXiDodDU036KbvQpQqAlhWkPfRwxB5x--Pj77pehGR1ux5RnQAtm2K9tYfQYx0Jv_bihQ4rJhb8hVzAMaaab3UvyrIdQ8NVxnpLvn86_nX2pLr9-Xp19vKycMsJWpgPXSaOwEarr151hGh3TsNZGMmkVlwJASNv1Xa1cI1AJsA60MNY5q5w8Je8Ouducfk5YxnbwxWEIEDFNpa210Upq_ajIja454_Usvv-_qJSUtRW1mtXlQXU5lZKxb7fZD5B3LWftvsZ2rrF9qHFeeHPMntYDdvf6sbeZvz1yKA5CnyE6X-41VavGNvuY5qDd-oC7R4625xerf174A957uIQ</recordid><startdate>199304</startdate><enddate>199304</enddate><creator>Gaillard, Jean‐Philippe</creator><creator>Bataille, Régis</creator><creator>Brailly, Hervé</creator><creator>Zuber, Caroline</creator><creator>Yasukawa, Kiyoshi</creator><creator>Attal, Michel</creator><creator>Maruo, Naoko</creator><creator>Taga, Tetsuya</creator><creator>Kishimoto, Tadamitsu</creator><creator>Klein, Bernard</creator><general>WILEY‐VCH Verlag GmbH</general><general>Wiley-VCH</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>199304</creationdate><title>Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy</title><author>Gaillard, Jean‐Philippe ; Bataille, Régis ; Brailly, Hervé ; Zuber, Caroline ; Yasukawa, Kiyoshi ; Attal, Michel ; Maruo, Naoko ; Taga, Tetsuya ; Kishimoto, Tadamitsu ; Klein, Bernard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4628-6dacd364e924dfbd605ec05ab5630384132aa238dfd74c92e42a8ca5268cc84c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Interleukin-6 - metabolism</topic><topic>Interleukin‐6</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Monoclonal gammopathy</topic><topic>Monoclonal Gammopathy of Undetermined Significance - blood</topic><topic>Multiple Myeloma - blood</topic><topic>Receptors, Immunologic - chemistry</topic><topic>Receptors, Immunologic - metabolism</topic><topic>Receptors, Interleukin-6</topic><topic>Solubility</topic><topic>Soluble interleukin‐6 receptor</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gaillard, Jean‐Philippe</creatorcontrib><creatorcontrib>Bataille, Régis</creatorcontrib><creatorcontrib>Brailly, Hervé</creatorcontrib><creatorcontrib>Zuber, Caroline</creatorcontrib><creatorcontrib>Yasukawa, Kiyoshi</creatorcontrib><creatorcontrib>Attal, Michel</creatorcontrib><creatorcontrib>Maruo, Naoko</creatorcontrib><creatorcontrib>Taga, Tetsuya</creatorcontrib><creatorcontrib>Kishimoto, Tadamitsu</creatorcontrib><creatorcontrib>Klein, Bernard</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gaillard, Jean‐Philippe</au><au>Bataille, Régis</au><au>Brailly, Hervé</au><au>Zuber, Caroline</au><au>Yasukawa, Kiyoshi</au><au>Attal, Michel</au><au>Maruo, Naoko</au><au>Taga, Tetsuya</au><au>Kishimoto, Tadamitsu</au><au>Klein, Bernard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy</atitle><jtitle>European journal of immunology</jtitle><addtitle>Eur J Immunol</addtitle><date>1993-04</date><risdate>1993</risdate><volume>23</volume><issue>4</issue><spage>820</spage><epage>824</epage><pages>820-824</pages><issn>0014-2980</issn><eissn>1521-4141</eissn><coden>EJIMAF</coden><abstract>Soluble human interleukin‐6 receptor (sIL‐6R) was measured in the serum of 30 healthy individuals, 32 individuals with monoclonal gammopathy of undetermined significance (MGUS), 20 patients with early multiple myeloma (MM) and 54 patients with overt MM. The serum activity recognized by an immunoradiometric assay was determined to be sIL‐6R, because of its binding capacity to IL‐6 and its molecular mass of 55 kDa.
All sera of healthy individuals contained sIL‐6R (mean value: 89 ng/ml, range 17‐300 ng/ml). Serum sIL‐6R levels were increased by 51% in patients with MGUS (mean value: 135 ng/ml, p<0.005), by 44% in patients with early myeloma (mean value: 128 ng/ml, p<0.001) and by 116 % in patients with overt MM (mean value: 193 ng/ml, p<0.001). In patients with MM, a complete lack of correlation (p>0.7) was found between serum sIL‐6R levels and other previously recognized prognostic factors in this disease, particularly serum IL‐6 levels and those factors related to tumor cell mass. The independence of serum sIL‐6R levels on tumor cell mass was directly demonstrated by studying four patients with MM treated with autologous bone marrow transplantation for periods of between 320 and 760 days. These levels were found to be remarkably stable and constant, independent of whether patients relapsed or achieved complete remission. Finally, physiological concentrations of sIL‐6R were found to increase by tenfold the sensitivity of human myeloma cell lines to IL‐6. These observations suggest a high control of the sIL‐6R level in vivo, and, possibly, an important functional role of this circulating protein in patients with monoclonal gammopathies.</abstract><cop>Weinheim</cop><pub>WILEY‐VCH Verlag GmbH</pub><pmid>8458373</pmid><doi>10.1002/eji.1830230408</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2980 |
| ispartof | European journal of immunology, 1993-04, Vol.23 (4), p.820-824 |
| issn | 0014-2980 1521-4141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75654355 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Biological and medical sciences Female Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Interleukin-6 - metabolism Interleukin‐6 Male Medical sciences Monoclonal gammopathy Monoclonal Gammopathy of Undetermined Significance - blood Multiple Myeloma - blood Receptors, Immunologic - chemistry Receptors, Immunologic - metabolism Receptors, Interleukin-6 Solubility Soluble interleukin‐6 receptor Time Factors |
| title | Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A49%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20and%20highly%20stable%20levels%20of%20functional%20soluble%20interleukin%E2%80%906%20receptor%20in%20sera%20of%20patients%20with%20monoclonal%20gammopathy&rft.jtitle=European%20journal%20of%20immunology&rft.au=Gaillard,%20Jean%E2%80%90Philippe&rft.date=1993-04&rft.volume=23&rft.issue=4&rft.spage=820&rft.epage=824&rft.pages=820-824&rft.issn=0014-2980&rft.eissn=1521-4141&rft.coden=EJIMAF&rft_id=info:doi/10.1002/eji.1830230408&rft_dat=%3Cproquest_cross%3E1443378274%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1443378274&rft_id=info:pmid/8458373&rfr_iscdi=true |